Serum Lipids and Thyroid Activity in Lupus Erythematosus: Modification with Propylthiouracil1  by Lynch, Francis W. & Krafchuk, John D.
SERUM LIPIDS AND THYROID ACTIVITY IN LUPTJS
ERYTHEMATOSUS: MODIFICATION WITH
PROPYLTHIOURACIL *
FRANCIS W. LYNCH, M.D. AND JOHN D. KRAFCHUK, M.D.
It has long been known that in lupus erythematosus there is disturbance of
the physiological chemistry and the endocrine relationships, but the details are
far from clear. Our interest in lipid metabolism in lupus erythematosus was
stimulated by the observation of a patient whose discoid lupus erythematosus
persisted for 28 years except for one period of 9 months when unrecognized and
uncontrolled diabetes was accompanied by hyperlipemia and extensive eruptive
xanthomatosis. t No one has yet suggested a satisfactory physiologic explanation
for these phenomena. Our interest was directed to the lipemia because the dis-
turbed metabolism of carbohydrate seemed not to be a likely explanation and
because the endocrine and chemical features of diabetes are so complex (e.g.,
albumin-globulin ratios and their possible influence on cholesterol metabolism).
A possible association between a disturbance of the lipids and lupus erythema-
tosus would suggest renewed consideration of thyroid metabolism and lupus
erythematosus, because of the known changes present in cholesterol metabolism
in hypothyroidism.
While it is difficult to alter blood lipid values by dietary factors alone, anti-
thyroid compounds, particularly propylthiouracil, offer a relatively safe and
effective means of raising serum cholesterol values. In addition, since some of the
manifestations of systemic lupus erythematosus, such as tachycardia, nervous-
ness, and intolerance to heat, are also seen with thyroid hyperactivity, observa-
tion of the effect of suppression of thyroid activity in patients with this disease
might be of interest.
METHOD
The present study of patients with lupus erythematosus was directed toward
inducing hypercholesteremia by the administration of propylthiouracil in dosage
* From the Division of Dermatology, University of Minnesota (Dr. H. E. Michelson,
Director).
Presented at the fifteenth annual meeting of The Society for Investigative Derma-
tology, Inc., San Francisco, California, June 20, 1954.
t Case Report (by F. W. L.): R. H., 39 years of age, was observed because of discoid
lupus erythematosus which had persisted for 12 years without evidence of systemic in-
volvement. He was next seen in 1940 with the eruption practically healed for 6 months
during which he had lost 40 lbs.; hundreds of xanthomas had appeared over the elbows,
knees and buttocks, with a few on the palms; and diabetes was recognized. When seen 5
months later with the diabetes controlled, the lupus erythematosus had recurred for 6
weeks. Hyperlipemia had been present in 1940 but returned to normal with recurrence of
the lupus erythematosus. In 1954 the eruption was still present, and the serum cholesterol
level was normal. (Because of the familial tendency in many lipemic disorders there may
he significance in the fact that a sister of this patient also has lupus erythematosus.)
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sufficient to cause mild hypothyroidism. Dosage of propyithiouracil began with
150 mg. and increased to 300 mg. daily. Instructions for high fat diets were also
given to all patients. An attempt was made to observe the patients at intervals
of two weeks, noting the clinical course, pulse rate, white blood cell total and
differential count, erythrocyte sedimentation rate, serum cholesterol level, total
serum lipids and basal metabolic rate. All clinical observations were made by
one clinician (J. D. K.).
RESULTS
Ten patients were so treated. In several there was failure to induce any ap-
preciable degree of hypothyroidism as measured by serum cholesterol levels or
by basal metabolic rate. Table I presents a summary of the clinical findings in
these ten patients. While this group was selected as having cutaneous manifes-
tations and prolonged courses, it will be noted that most of the patients pre-
sented evidence of systemic activity, particularly malaise and easy fatiguability.
Toxicity from therapy was evident in only one patient (number 4), in whom
there was marked loss of smell and taste which led to discontinuance of therapy
at 73 days. The pulse rate was checked briefly to recognize decreasing thyroid
function which might not be noted by other methods. The observed changes are
of no particular note in this study.
The total and differential white blood cell counts were done for recognition of
TABLE I
Clinical data on ten patients with chronic or subacute lupus
erythematosus given pro pyithiouracil
Patient Sex Age
Eruption
Man'festationsLu
tion Location Severity(years)
1. M. I. F 28 7 scalp, forehead,
nose, cheek
moderate —
2. E. R. F 60 8 scalp, cheek, nose mild malaise
arthralgia
3. H. F. F 42 15 scalp, face, neck,
arms
marked malaise
arthralgia
fever
4. G. D. F 32 6 cheeks, nose moderate —
5. B. E. F 69 12 face mild malaise
arthralgia
purpura
fever
6. M. R. F 38 9 scalp, neck, face,
buccal
moderate malaise
arthralgia
7. M. C. F 46 33 scalp, face moderate —
8. A. L. M 51 7 face, neck, arms marked malaise
arthralgia
9. G. Y. F 31 4 face, neck, arms mild malaise
10. D. 0. F 27 2 face, arms, legs marked malaise
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TABLE II
Results of therapy with propylthiouracil, 150 to 800 mgms. by moulh daily, in ten patients
with lupus erythematosus: dosage and clinical results
Therapy
Patient
Duration Dosage
(days) (grams)
B.M.R. Cholesterol
With no During
therapy therapy C ange
With no
therapy
During
therapy C ange
With no
therapy
During
therapy Change
1. M. I.
2. E. R.
3. H. F.
4. G. D.
5. B. E.
6. M. R.
7. M. C.
8. A. L.
9. G. Y.
10. D. 0.
606
54
225
73
120
56
427
157
52
50
146
13
65
13
19
16
122
47
11
10
35
67
55
55
97
36
12
45
32
35
33
61
46
25
89
35
11
32
29
31
—2
—6
—9
—30
—8
—1
—1
—13
—3
—4
+27
—
—31
+2
—
—2
+36
+8
+4
—14
+12
—13
—17
—7
+9
+1
+15
+1
+5
—12
—15
—
+14
—9
—
+3
—11
—7
+1
+2
104
172
162
197
125
224
201
196
180
162
202
246
199
340
138
233
158
220
192
175
+102
+74
+37
+143
+13
+9
—43
+24
+12
+13
TABLE III
Clinical response to therapy; patients listed in order of influence on serum cholesterol
Patient Clinical Change
4. G. D.
1. M. I.
2. E. R.
3. H. F.
8. A. L.
5. B. E.
10. D. 0.
9. G. Y.
6. M. R.
7. M. C.
+143
+102
+74
+37
+24
+13
+13
+12
+9
—43
1+
3+
2+
1+
0
0
0
0
slight to moderate improvement
almost complete clearing
50% improvement
cutaneous and symptomatic improvement
sedimentation rate decreased
continued to improve
no response
no response
slight improvement; continued activity
no response
possible toxicity from the thiouracil or activation of the lupus erythematosus.
The observed changes were insignificant. Previous to treatment 5 patients had
counts below 5000.
Average total serum lipid values previous to and following therapy were nor-
mal; the slight changes were without apparent relation to other observed data.
Other responses to treatment are tabulated (Table II).
In each instance there was some decrease in the average pre- and post-treat-
ment values for the sedimentation rate but in only 2 patients (numbers 4 and 8)
was the change significantly large.
No consistent pattern of depression of the BMR by propylthiouracil was
apparent in this group, and there was no relationship to the clinical response.
Of chief interest in the study is comparison of the clinical course and the
changes in serum cholesterol levels during administration of propyithiouracil
(Table III). In a series of such limited number it is recognized that conclusions
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must be qualified because of the natural variations in the clinical course of this
disease and in the inconsistencies in reports of cholesterol values. However, two
general statements can be made.
1. Pre-treatment values for serum cholesterol were consistently in the lower
half of the normal range (150—300 mg.) for the laboratory concerned.
2. The clinical improvement correlated with increases in cholesterol levels.
Figures varied widely in a comparison of values during and without propyithi-
ouracil therapy (both before and after), but the greatest increase in cholesterol
values was found in those individuals manifesting clinical improvement. Al-
though the relationship is not strictly quantitative, some clinical improvement
occurred in all patients whose cholesterol values increased significantly.
COMMENT
The significance of these observations is not clear and the observations them-
selves require repetition and expansion. Did the induced hypothyroidism directly
affect the lupus erythematosus? Or did it lead indirectly to increased adrenal or
pituitary output and thus treat the disease with added amounts of the patients'
cortisone or corticotropin? Or did the hypercholesteremia influence the lupus
erythematosus in some inexplicable manner? Based on our experience it would
now seem safe to experiment further by use of larger dosage to obtain greater
inactivation of the thyroid gland. Hypothyroidism without hypercholesteremia
might conceivably result from administering heparin (a substance recently men-
tioned for therepeutic trial in lupus erythematosus) (1).
Previous experimental studies have not clarified the influence of thiouracil on
the pituitary-adrenal axis. It is reported that the administration of thiouracil
to the rat causes involution of the adrenal cortex (perhaps due to decreased
pituitary output of adrenocorticotrophic hormone) (2). In apparent contrast, in
white leghorn cockerels both thiouracil and thyroidectomy resulted in doubling
of the relative adrenal weight (functional output was not determined) (3). In
the rat after thiouracil caused cortical involution, the involuted cortex was found
functionally able to hypertrophy as a result of infection elsewhere (4). Without
hormonal assays in our patients it is impossible to know what may have helped
their lupus erythematosus.
CONCLUSIONS
It is absolutely not the purpose of this report to suggest that the induction of
hypothyroidism can at this time be considered useful in the treatment of lu-
pus erythematosus. These data are recorded in the hope of stimulating further
studies that may ultimately clarify the presently confusing endocrine relation-
ships of lupus erythematosus.
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DISCUSSION
DR. ALLAN L. L0RINCz (Chicago, Ill.): I was very much interested in hearing
this paper because at the University of Chicago Clinics a small series of patients
with acute and subacute disseminated lupus erythematosus have been treated
with radioactive iodine on an experimental basis.
Interest in this approach was aroused about two years ago when we observed
a patient with classical subacute lupus erythematosus who, before being seen
by the dermatologists, was treated with radio-iodine under the erroneous diagno-
sis of hyperthyroidism. Within a month after this treatment, all the lupus
erythematosus lesions spectacularly resolved. Since then, Dr. D. M. Bergenstal
of the Department of Medicine has treated five additional cases of disseminated
lupus erythematosus with doses of radio-iodine sufficient to induce hypothy-
roidism. In at least two of these cases with acute lupus erythematosus definite
benefit was obtained. The others have not yet been followed long enough after
radio-iodine administration to evaluate results but early impressions have been
encouraging. It will be interesting to see whether the so far good therapeutic
results in this series can also be correlated with the degree of elevation of blood
lipids accompanying the induced hypothyroidism.
DR. JOHN R. HASERICK (Cleveland, Ohio): I enjoyed Dr. Lynch's customarily
well-prepared study and wish to add a group of twelve patients with systemic
lupus erythematosus treated with propylthiouracil.
We came to the use of this medication via a somewhat circuitous route. In
the early days of steroid therapy the possibility of corticogenic hypothyroidism
was considered to be one of the side reactions to the prolonged administration
of cortisone or corticotrophin. Some authorities recommended the use of thyroid
extract along with cortisone to counteract this tendency.
Therefore, for a while we used thyroid extract along with steroid therapy in
the treatment of systemic lupus erythematosus. To our dismay these patients
became worse, and, instead of decreasing their daily cortisone requirement, ac-
tually needed more of the drug in order to control the disease.
We obtained some thyroid stimulating hormone (TSR) from Armour and
Company and gave it to three patients with systemic lupus erythematosus.
Prior to its administration all three of them were in a clinical remission. After
one month of TSR therapy, each of these patients was considerably worse and
the two with the negative L.E. tests had strongly positive reactions.
Then we went on a program of inducing hypothyroidism in systemic lupus
erythematosus. We have treated these patients with propyithiouracil over the
past two to two and one half years. We were unable to come to any real conclu-
sion as to the effects on these patients with propylthiouracil. We felt that some
of them showed some improvement, but it was not striking.
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Finally, we selected one patient whose disease had been particularly worsened,
first, by the use of thyroid extract, and, secondly, by TSH therapy. A state of
complete myxedema was induced with radioactive iodine. Instead of improving,
this patient's lupus erythematosus went from bad to worse. She is now in a
euthyroid state on thyroid extract. The activity of her systemic lupus erythema-
tosus is again under control with cortisone and the maintenance program is
much more tranquil than when she was either in a hyperthyroid or hypothyroid
state.
Dx. CHARLES R. REIN (New York, N. Y.): Doctors Lynch and Krafchuk are
to be congratulated on their most interesting and worthwhile presentation.
Publications by the Mayo Clinic group and by Dr. Kostant and myself have
shown that many presumably nonsyphilitic individuals with lupus erythemato-
sus develop positive serologic tests for syphilis with the standard procedures.
Information is requested as to whether any of the patients in your series had
positive STS, and if there was a reversal to seronegativity following thyroid
therapy?
Dx. HERMAN BEERMAN (Philadelphia, Penna.): I would like to address this
question to Dr. Haserick, rather than to Dr. Lynch. Didn't Dr. Netherton some
years ago report on a patient with lupus erythematosus with xanthoma? In
which case, I would like to raise the question, then, of Dr. Lynch, how does he
explain the co-existence of two conditions which he feels now might be antag-
onistic?
Dx. FRANCIS W. LYNCH (in closing): I wish to thank each of the discussors
for his interest and comments. In reply to Dr. Rein, none of these patients pre-
sented positive serologic reactions for syphilis.
